



MARIN POZO JF ¹, CAO VIÑA V ¹, MARÍN CABA E ², PLAZA ARBEO A ¹, GUTIÉRREZ LUCENA L ¹, CONTRERAS COLLADO R ¹
¹ HOSPITAL UNIVERSITARIO DE JAÉN, JAÉN
² HOSPITAL UNIVERSITARIO SAN CECILIO, GRANADA

OBJECTIVES

The treatment of SCNM in patients with ALK alteration is performed with targeted therapies. The benefit of this therapy is associated with a significant increase in costs. In this study it is intended:

- To analyze the effectiveness of treatment at non-small-cell lung cancer (NSCLC with anaplastic lymphoma kinase inhibitors (ALK-i).
- To describe the costs associated with the therapy


METHODS

- Retrospective observational study in real clinical practice .
- All patients treated with ALK-i for NSCLC from January 2016 to April 2023 in a reference hospital in oncology in southern Spain were included.
- The effectiveness variable: Progression-free survival (PFS)
- Economic variable was the cost of treatment.
- Kaplan-Meier analysis, measures of central tendency or dispersion and frequency analysis according to variable were performed.


RESULTS

- Thirty-one treatments corresponding to 21 patients (52% male) were analyzed, eight patients were treated with two or more ALK-i.
- Mean age was 54.1 years (range: 21-78).
- Performance status was 86% ECOG 0-1, 14 % ECOG 2.
- 10 Patients had chemotherapy prior to ALK-inhibitor therapy
- The mean duration therapy with ALK-inhibitors was 24 months: 28 months for Alectinib, 14 for Crizotinib and 12 for Lorlatinib.
- Ten patients on alectinib, one on lorlatinib and none on crizotinib remained on treatment at the cut-off date.


Nº Treatments



Treatments by line therapy




Drugs and Line of Therapy




-Median PFS was 20.2 months for the entire population.

- For Crizotinib:
 - 15.3 months [95% CI: 0.5-30.2].
- For Lorlatinib
 - 12 months [95% CI: 0-24 .8].
- Alectinib did not reach the number of events needed to calculate the median,
 - the mean was estimated at 35.7 m [95%CI: 24.8-46.6].
 - For 8 of 13 alectinib patients censored for PFS its value was >29 months (range 29.5-56.8)

-1st line of therapy all ALK-i.
Median PFS was 21,2 months



-2nd line of therapy all ALK-I
Median PFS was 15,3 months



The total cost of ALK-i at the cut-off date was €1,906,002 and the mean cost with ALK-i/treatment was €61,484.
The median treatment cost by progression-free month was €3,043.

CONCLUSIONS

Alectinib showed greater effectiveness than crizotinib and lorlatinib, although the follow-up time was short and the number of patients and type of therapy differed between the three drugs.
ALK-i showed comparable effectiveness to that obtained in clinical trials, the clinical benefit that would justify the cost of the drug.